Fang Yixuan, Chen Lihong, Sun Shiyi, Ran Xingwu
Department of Endocrinology & Metabolism, West China Hospital, Sichuan University, Chengdu 610041, China.
Innovation Center for Wound Repair, Diabetic Foot Care Center, West China Hospital, Sichuan University, Chengdu 610041, China.
J Cardiovasc Dev Dis. 2024 Jun 28;11(7):198. doi: 10.3390/jcdd11070198.
Several studies have shown that sodium-dependent glucose transporter 2 inhibitors can be used in the treatment of heart failure. This article summarized systematic reviews of sodium-dependent glucose transporter 2 inhibitors in the treatment of heart failure in order to evaluate efficacy and safety. We systematically searched eight electronic databases from inception to July 2023. We used Assessment of Multiple Systematic Reviews 2 to evaluate the methodological quality, the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 to assess report quality, Risk of Bias in Systematic Review to assess the risk of bias, and Grading of Recommendations Assessment, Development, and Evaluation to rate the quality of evidence. A total of 36 systematic reviews were included. Our results were classified as clear evidence of benefit: hospitalization for heart failure; possible benefit: cardiovascular death (mortality) and renal outcome composite; clear evidence of no effect or equivalence: atrial arrhythmias, ventricular arrhythmia, atrial fibrillation, and hypotension; possible harm: genital infection; insufficient evidence to draw a conclusion: atrial flutter, major adverse cardiovascular events, urinary tract infection, acute kidney injury, hypoglycemia, and bone fracture. Sodium-dependent glucose transporter 2 inhibitors are beneficial for the treatment of heart failure, especially in terms of heart failure hospitalization.
多项研究表明，钠-葡萄糖协同转运蛋白2抑制剂可用于治疗心力衰竭。本文总结了钠-葡萄糖协同转运蛋白2抑制剂治疗心力衰竭的系统评价，以评估其疗效和安全性。我们系统检索了从数据库建立至2023年7月的八个电子数据库。我们使用《多种系统评价评估2》评估方法学质量，使用《系统评价和Meta分析的首选报告项目2020》评估报告质量，使用《系统评价中的偏倚风险》评估偏倚风险，并使用《推荐分级评估、制定和评价》对证据质量进行评级。共纳入36项系统评价。我们的结果分类如下：有明确获益证据的：因心力衰竭住院；可能获益的：心血管死亡（死亡率）和肾脏结局复合指标；有明确无效应或等效证据的：房性心律失常、室性心律失常、心房颤动和低血压；可能有害的：生殖器感染；证据不足无法得出结论的：心房扑动、主要不良心血管事件、尿路感染、急性肾损伤、低血糖和骨折。钠-葡萄糖协同转运蛋白2抑制剂对心力衰竭治疗有益，尤其是在心力衰竭住院方面。
